

DAFTAR PUSTAKA

- Abe, M., Kaizu, K., & Matsumoto, K. (2007). Evaluation of the Hemodialysis-induced Changes in Plasma Glucose and Insulin Concentrations in Diabetic Patients: Comparison Between the Hemodialysis and Non-hemodialysis Days. *Therapeutic Apheresis and Dialysis*, 11(4), 288–295. <https://doi.org/10.1111/j.1744-9987.2007.00492.x>
- Amini, M., Aghighi, M., Masoudkabir, F., Zamyadi, M., Norouzi, S., Rajolani, H., Rasouli, M.-R., & Pourbakhtyaran, E. (2011). Hemodialysis adequacy and treatment in Iranian patients: a national multicenter study. *Iranian journal of kidney diseases*, 5(2), 103–109.
- Anggreani, N., Rusli, R., Annisa, N., Penelitian, L., Pengembangan, D., & Tropis, F. (2017). *Proceeding of the 5 th Mulawarman Pharmaceuticals Conferences, KESESUAIAN WAKTU PEMBERIAN OBAT HEMODIALISA DI RSUD A.W SJAHRANIE SAMARINDA*.
- Armiyati, Y. (2012). Hipotensi dan Hipertensi Intradialisis pada Pasien Chronic Kidney Disease (CKD) Saat Menjalani Hemodialisis di RS PKU Muhammadiyah Yogyakarta. *Jurnal Universitas Muhammadiyah Semarang*, 126–135.
- Arnouts, P., Bolignano, D., Nistor, I., Bilo, H., Gnudi, L., Heaf, J., & Van Biesen, W. (2014). Glucose-lowering drugs in patients with chronic kidney disease: A narrative review on pharmacokinetic properties. Dalam *Nephrology Dialysis Transplantation* (Vol. 29, Nomor 7, hlm. 1284–1300). Oxford University Press. <https://doi.org/10.1093/ndt/gft462>
- Baldwin, D., Zander, J., Munoz, C., Raghu, P., DeLange-Hudec, S., Lee, H., Emanuele, M. A., Glossop, V., Smallwood, K., & Molitch, M. (2012). A Randomized Trial of Two Weight-Based Doses of Insulin Glargine and Glulisine in Hospitalized Subjects With Type 2 Diabetes and Renal Insufficiency. *Diabetes Care*, 35(10), 1970–1974. <https://doi.org/10.2337/dc12-0578>
- Brar, S. K., Perveen, S., Chaudhry, M. R., AlBabtain, S., Amreen, S., & Khan, S. (2021). Erythropoietin-Induced Hypertension: A Review of Pathogenesis, Treatment, and Role of Blood Viscosity. *Cureus*, 13(1), e12804. <https://doi.org/10.7759/cureus.12804>
- Brenner, B. M., Levine, S. A., Rector, F. C., Himmelfarb, J., Chuang, P., & Schulman, G. (2008). Hemodialysis. Dalam *Brenner & Rector's The Kidney* (8 ed.).
- Bucharles, S. G. E., Wallbach, K. K. S., Moraes, T. P. de, & Pecoits-Filho, R. (2019). Hypertension in patients on dialysis: diagnosis, mechanisms, and management. Dalam *Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia* (Vol. 41,

- Nomor 3, hlm. 400–411). NLM (Medline). <https://doi.org/10.1590/2175-8239-JBN-2018-0155>
- Burmeister, J. E., Miltersteiner, D. da R., Burmeister, B. O., & Campos, J. F. (2015). Risk of hypoglycemia during hemodialysis in diabetic patients is related to lower pre-dialysis glycemia. *Archives of Endocrinology and Metabolism*, 59(2), 137–140. <https://doi.org/10.1590/2359-3997000000026>
- Chang, T. I., Tatoian, E. T., Montez-Rath, M. E., & Chertow, G. M. (2021). Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis: A Cluster Randomized Trial. *Kidney360*, 2(11), 1752–1760. <https://doi.org/10.34067/kid.0001922021>
- Christopher W., M., & James O., B. (2014). Dialysis. *BMJ*, 348. <https://doi.org/10.1136/bmj.g2>
- Dhrik, M., & Prasetya, A. A. N. P. R. (2019). Kajian Pemilihan Obat Antihipertensi Pada Penderita Hipertensi Dengan Gagal Ginjal Kronis Yang Menjalani Hemodialisis. *Acta Holistica Pharmadana*, 2(1), 18–26.
- DiPiro, J. T., Yee, G. C., Posey, L. M., Haines, S. T., Nolin, T. D., & Ellingrod, V. L. (2020). *Pharmacotherapy: A pathophysiologic approach* (11 ed.). McGraw Hill Medical.
- Douma, L. G., & Gumz, M. L. (2018). Circadian clock-mediated regulation of blood pressure. *Free radical biology & medicine*, 119, 108–114. <https://doi.org/10.1016/j.freeradbiomed.2017.11.024>
- Elung-Jensen, T., Strandgaard, S., & Kamper, A.-L. (2008). Longitudinal observations on circadian blood pressure variation in chronic kidney disease stages 3-5. *Nephrology Dialysis Transplantation*, 23(9), 2873–2878. <https://doi.org/10.1093/ndt/gfn126>
- Georgianos, P. I., & Agarwal, R. (2016). Pharmacotherapy of hypertension in chronic dialysis patients. Dalam *Clinical Journal of the American Society of Nephrology* (Vol. 11, Nomor 11, hlm. 2062–2075). American Society of Nephrology. <https://doi.org/10.2215/CJN.00870116>
- Gracia, M., & Hendro, G. (2021). GAMBARAN ADAPTASI FISIOLOGIS DAN PSIKOLOGIS PADA PASIEN GAGAL GINJAL KRONIS YANG MENJALANI HEMODIALISIS DI KOTA MANADO. Dalam *Jurnal Keperawatan* (Vol. 9, Nomor 2).
- Hahr, A. J., & Molitch, M. E. (2015). Management of diabetes mellitus in patients with chronic kidney disease. *Clinical Diabetes and Endocrinology*, 1(1). <https://doi.org/10.1186/s40842-015-0001-9>
- Hakiki, A. F. (2015). *ANALISIS FAKTOR FAKTOR YANG MEMPENGARUHI KEPATUHAN ASUPAN CAIRAN DAN NUTRISI*

*PADA KLIEN HEMODIALISA DI RS PKU MUHAMMADIYAH
YOGYAKARTA NASKAH PUBLIKASI.*

Hasibuan, L. (2022, Oktober 14). *Layanan Cuci Darah Bisa Ditanggung BPJS, Ini Syaratnya!*
<https://www.cnbcindonesia.com/lifestyle/20221014100649-33-379689/layanan-cuci-darah-bisa-ditanggung-bpjs-ini-syaratnya#:~:text=Ada%20yang%20dua%20kali%20seminggu,2%20kali%20seminggu%20per%20pasien.>

Inrig, J. K. (2010). Antihypertensive agents in hemodialysis patients: A current perspective. Dalam *Seminars in Dialysis* (Vol. 23, Nomor 3, hlm. 290–297). <https://doi.org/10.1111/j.1525-139X.2009.00697.x>

Inrig, J. K., Patel, U. D., Toto, R. D., & Szczech, L. A. (2009). Association of Blood Pressure Increases During Hemodialysis With 2-Year Mortality in Incident Hemodialysis Patients: A Secondary Analysis of the Dialysis Morbidity and Mortality Wave 2 Study. *American Journal of Kidney Diseases*, 54(5), 881–890. <https://doi.org/10.1053/j.ajkd.2009.05.012>

International Diabetes Federation. (2020). *Diabetes prevalence (% of population ages 20 to 79) - Indonesia*. <https://data.worldbank.org/indicator/SH.STA.DIAB.ZS?locations=ID>.

Ivanovna, O. E. (2020). *Hemapo*. https://pillintrip.com/medicine/hemapo#desc_10.

Jackson, M. A., Holland, M. R., Nicholas, J., Lodwick, R., Forster, D., & Macdonald, I. A. (2000). Hemodialysis-induced hypoglycemia in diabetic patients. *Clinical nephrology*, 54(1), 30–34.

KalbeMed. (2023). *Hemapo*. <https://kalbemed.com/product/id/281>.

Kallenbach, J. Z. (2014). *Review of Hemodialysis for nurses and dialysis personnel*. Elsevier Health Sciences.

Karyadi. (2022). Quick Blood berhubungan dengan ktv (Karyadi, 2022). *Indonesian Journal of Medicine and Health*, 2(3), 597–603.

Kazancioğlu, R. (2013). Risk factors for chronic kidney disease: An update. *Kidney International Supplements*, 3(4), 368–371. <https://doi.org/10.1038/kisup.2013.79>

Kementerian Kesehatan Indonesia. (2013). *Kamus Glukosa*. <https://www.kemkes.go.id/index.php?txtKeyword=glukosa&act=search-by-map&pgnumber=0&charindex=&strucid=1280&fullcontent=1&C-ALL=1>.

Kementerian Kesehatan Republik Indonesia. (2018). *Hasil Utama Riskesdas 2018*.

- Kementerian Kesehatan Republik Indonesia. (2022). *PERATURAN MENTERI KESEHATAN REPUBLIK INDONESIA NOMOR 24 TAHUN 2022 TENTANG REKAM MEDIS*.
- Khan, T. M., Patel, R., & Siddiqui, A. H. (2022). Furosemide. Dalam *StatPearls*. StatPearls Publishing.
<https://www.ncbi.nlm.nih.gov/books/NBK499921/>
- Kidney Disease Improving Global Outcome. (2013). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney International Supplement*, 3(1), 1–150.
www.publicationethics.org
- Kidney Disease Improving Global Outcomes. (2021). KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. *Kidney International Supplement*, 99(3S).
- Kovesdy, C. P. (2022). Epidemiology of chronic kidney disease: an update 2022. Dalam *Kidney International Supplements* (Vol. 12, Nomor 1, hlm. 7–11). Elsevier B.V. <https://doi.org/10.1016/j.kisu.2021.11.003>
- Kuipers, J., Verboom, L. M., Ipema, K. J. R., Paans, W., Krijnen, W. P., Gaillard, C. A. J. M., Westerhuis, R., & Franssen, C. F. M. (2019). The Prevalence of Intradialytic Hypotension in Patients on Conventional Hemodialysis: A Systematic Review with Meta-Analysis. *American Journal of Nephrology*, 49(6), 497–506.
<https://doi.org/10.1159/000500877>
- Lemeshow, S., Hosmer, D. W., Klar, J., & Lwanga, S. K. (1997). *Besar sampel dalam penelitian kesehatan*. Gadjah Mada University Press.
- Liu, Y., Ma, X., Zheng, J., Jia, J., & Yan, T. (2017). Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: A meta-analysis of randomised controlled trials. *BMC Nephrology*, 18(1).
<https://doi.org/10.1186/s12882-017-0605-7>
- Marianna, S., & Astutik, S. (2019). Hubungan Dampak Terapi Hemodialisa Terhadap Kualitas Hidup Pasien dengan Gagal Ginjal. *Indonesian Journal of Nursing Sciences and Practice*, 41–52.
- Medscape. (2023). *Hydrochlorothiazide* (Rx).
<https://reference.medscape.com/drug/microzide-hydrodiuril-hydrochlorothiazide-342412>.
- Mistry, K. (2019). Dialysis disequilibrium syndrome prevention and management. Dalam *International Journal of Nephrology and Renovascular Disease* (Vol. 12, hlm. 69–77). Dove Medical Press Ltd.
<https://doi.org/10.2147/IJNRD.S165925>

- National Institute of Health. (2022). *Hemodialysis*. U.S. Department of Health and Human Services. <https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/hemodialysis>
- National Kidney Foundation. (2005). K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. *American journal of kidney diseases : the official journal of the National Kidney Foundation*, 45(4 Suppl 3), S49–S57. <https://doi.org/10.1053/j.ajkd.2005.01.019>
- National Kidney Foundation. (2015). KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. *Am J Kidney Dis*, 66(5), 884–930.
- National Kidney Foundation. (2023). *Kidney Failure Risk Factor: Gender (Sex)*. <https://www.kidney.org/content/kidney-failure-risk-factor-gender-sex>. <https://www.kidney.org/content/kidney-failure-risk-factor-gender-sex>
- Noshad, H. (2013). Blood pressure increase after erythropoietin injection in hemodialysis and predialysis patients. *Iranian journal of kidney diseases*, 7(3), 220–225.
- Pan American Health Organization. (2020). *World Hypertension Day 2020*. <https://www.paho.org/en/campaigns/world-hypertension-day-2020>.
- Panma, Y. (2018). Hubungan Karakteristik Individu dengan Kualitas Hidup Pasien Hemodialisis. *Buletin Kesehatan*, 2(1), 80–91.
- Parra, D., Roman, Y. M., Anastasia, E., & Straka, R. J. (2017). *Hypertension*.
- Perhimpunan Dokter Hipertensi Indonesia. (2019). *Konsensus Hipertensi Indonesia 2019*.
- Perhimpunan Nefrologi Indonesia. (2003). *Konsensus Dialisis* (1 ed.).
- Perkumpulan Endokrinologi Indonesia. (2019). *Pedoman Pengelolaan dan Pencegahan Diabetes Mellitus Tipe 2 Dewasa di Indonesia*. PB Perkeni.
- Retnawati, H. (2017). *Teknik Pengambilan Sampel*.
- Sapra, A., & Bhandari, P. (2022). *Diabetes Mellitus*. <https://www.ncbi.nlm.nih.gov/books/NBK551501/>
- Schepers, E., Glorieux, G., Eloit, S., Hulko, M., Boschetti-de-Fierro, A., Beck, W., Krause, B., & Van Biesen, W. (2018). Assessment of the association between increasing membrane pore size and endotoxin permeability using a novel experimental dialysis simulation set-up. *BMC nephrology*, 19(1), 1. <https://doi.org/10.1186/s12882-017-0808-y>
- Schonder, K. S. (2020). *Chronic and End-Stage Renal Disease*.
- Shahgholian, N., Ghafourifard, M., & Mortazavi, M. (2008). Impact of Two Types of Sodium and Ultrafiltration Profiles on Intradialytic Hypotension

- in Hemodialysis Patients. *Iranian Journal of Nursing and Midwifery Research*, 13(4), 135–139.
<https://www.researchgate.net/publication/228740048>
- Siagian, Y., Alit, D. N., & Suraidah. (2021). Analisis Faktor Yang Berhubungan dengan Kepatuhan Pembatasan Asupan Cairan Pasien Hemodialisa. *Jurnal Menara Medika*, 4(1), 71–80.
- Situmorang, T. D. (2022, Maret 27). *Pentingnya Adekuasi Hemodialisis untuk Hidup yang Lebih Baik*. <https://kpcdi.org/2022/03/27/pentingnya-adekuasi-hemodialisis-untuk-hidup-yang-lebih-baik/>.
- Sudha, M. J., Salam, H. S., Viveka, S., & Udupa, A. L. (2017). Assessment of changes in insulin requirement in patients of type 2 diabetes mellitus on maintenance hemodialysis. *Journal of Natural Science, Biology and Medicine*, 8(1), 64–68. <https://doi.org/10.4103/0976-9668.198348>
- Sulowicz, W., & Radziszewski, A. (2006). Pathogenesis and treatment of dialysis hypotension. *Kidney International*, 70(SUPPL. 104), 536–539. <https://doi.org/10.1038/sj.ki.5001975>
- Sun, C. Y., Lee, C. C., & Wu, M. S. (2009). Hypoglycemia in diabetic patients undergoing chronic hemodialysis. *Therapeutic Apheresis and Dialysis*, 13(2), 95–102. <https://doi.org/10.1111/j.1744-9987.2009.00662.x>
- Tieu, A., Velenosi, T. J., Kucey, A. S., Weir, M. A., & Urquhart, B. L. (2018). β -blocker dialyzability in maintenance hemodialysis patients a randomized clinical trial. *Clinical Journal of the American Society of Nephrology*, 13(4), 604–611. <https://doi.org/10.2215/CJN.07470717>
- Van Buren, P. N., & Inrig, J. K. (2016). Mechanisms and Treatment of Intradialytic Hypertension. *Blood purification*, 41(1–3), 188–193. <https://doi.org/10.1159/000441313>
- Warsono, E. D. (2022, Agustus 3). *Mengenal Adekuasi Hemodialisis Bagi Pasien Cuci Darah*. https://yankes.kemkes.go.id/view_artikel/918/mengenal-adekuasi-hemodialisis-bagi-pasien-cuci-darah.
- WebMD. (2023). *Epoetin Alfa Solution - Uses, Side Effects, and More*. <https://www.webmd.com/drugs/2/drug-1023/epoetin-alfa-injection/details>.
- Weinstein, J. R., & Anderson, S. (2010). The Aging Kidney: Physiological Changes. Dalam *Advances in Chronic Kidney Disease* (Vol. 17, Nomor 4, hlm. 302–307). <https://doi.org/10.1053/j.ackd.2010.05.002>
- World Health Organization. (2022). *Diabetes*. https://www.who.int/health-topics/diabetes#tab=tab_1.

Zepeda-Orozco, D., & Quigley, R. (2012). Dialysis disequilibrium syndrome. Dalam *Pediatric Nephrology* (Vol. 27, Nomor 12, hlm. 2205–2211). <https://doi.org/10.1007/s00467-012-2199-4>

Zhang, J., Sun, R., Jiang, T., Yang, G., & Chen, L. (2021). Circadian Blood Pressure Rhythm in Cardiovascular and Renal Health and Disease. *Biomolecules*, 11(6), 868. <https://doi.org/10.3390/biom11060868>